5-Amino-4-cyano-1-(n-pentyl)pyrazole | 89159-00-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-Amino-4-cyano-1-(n-pentyl)pyrazole
• 英文别名: 5-Amino-4-cyano-1-pentylpyrazole；5-Amino-1-pentyl-4-cyanopyrazole；5-Amino-1-pentyl-1H-pyrazole-4-carbonitrile；1H-Pyrazole-4-carbonitrile, 5-amino-1-pentyl-；5-amino-1-pentylpyrazole-4-carbonitrile
• CAS: 89159-00-2
• 化学式: C₉H₁₄N₄
• 分子量: 178.237
• InChiKey: GSWDIGMRMLMABI-UHFFFAOYSA-N

物化性质

• 沸点：
  355.0±27.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  67.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-Amino-4-cyano-1-(n-pentyl)pyrazole 在 对甲苯磺酸 、 cadmium(II) chloride 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 生成 4-Amino-6,7-dihydro-1-pentyl-6-propylpyrazolo<3,4-b>pyrrolo<3,4-e>pyridin-5(1H)-one
  参考文献：
  名称：

  Synthesis of Tricyclic Aminopyridines by a Cadmium Promoted Cyclization

  摘要：

  A novel cyclocondensation of o-amino nitriles with cyclic 1,3-diones has been developed as a synthetic route to assemble fused tricyclic aminopyridine derivatives. The reaction sequence involves the initial formation of an enaminone. The enaminone is then cyclized at 120 degrees C to 190 degrees C in the presence of Lewis acids which include zinc, cadmium and copper(I) salts. The cyclization may be promoted under more mild conditions by first deprotonating the enaminone to form the anion followed by exposure to cadmium(II) salts at 60 degrees C to 90 degrees C. Alternatively the enaminones may be reacted with organocadmium reagents such as dibutylcadmium to effect the deprotonation and cyclization directly at room temperature. Synthetic applications of these novel cadmium-mediated cyclizations are presented and mechanistic considerations discussed.

  DOI：

  10.1021/jo00121a048
• 作为产物：
  描述：

  N-戊基肼盐酸盐 、 乙氧基亚甲基丙二腈 以 乙醇 为溶剂， 反应 18.5h， 以to afford 7.73 g (88%) of the title compound的产率得到5-Amino-4-cyano-1-(n-pentyl)pyrazole
  参考文献：
  名称：

  Pyrazolopyridine cycloalkanones and process for their preparation

  摘要：

  本发明涉及新型四氢吡唑并[3,4-b]喹啉酮、环戊[b]吡唑并[4,3-e]吡啶酮和环庚[b]-吡唑并[4,3-e]吡啶酮，它们作为具有减少副作用的抗焦虑药物，包括制备方法、含有它们的制药组合物以及用于它们的制备的中间体。

  公开号：

  US04546104A1

文献信息

• Process for preparing pyrazolopyridine compounds
  申请人：ICI Americas Inc.

  公开号：US04563525A1

  公开（公告）日：1986-01-07

  Compounds of the formula (I): ##STR1## wherein R.sup.4 is hydrogen, D is oxygen or NR.sup.6, R.sup.1, R.sup.3, R.sup.6, R.sup.7 and R.sup.8 have defined values, and n is 1 or 2 are produced by internally cyclizing a compound of the formula (XV): ##STR2## wherein R.sup.19 is a value of R.sup.1 or hydrogen and, if R.sup.19 is hydrogen, reacting the cyclization product with R.sup.1 --Br and a weak base such as potassium carbonate.

  公式（I）的化合物：##STR1## 其中R.sup.4是氢，D是氧或NR.sup.6，R.sup.1，R.sup.3，R.sup.6，R.sup.7和R.sup.8具有定义的值，n为1或2，通过内部环化化合物的方法制备（XV）的化合物：##STR2## 其中R.sup.19是R.sup.1或氢的值，如果R.sup.19是氢，则将环化产物与R.sup.1-Br和弱碱（如碳酸钾）反应。
• CNS-Depressant pyrazolopyridines
  申请人：ICI Americas Inc.

  公开号：US04511568A1

  公开（公告）日：1985-04-16

  Compounds of the formula (I): ##STR1## wherein R.sup.1, R.sup.3, R.sup.4, R.sup.7 and R.sup.8 are as described herein, D is oxygen or NR.sup.6, n is 1 or 2 and the physiologically acceptable salts thereof useful in reducing anxiety in an animal such as man. The compounds are potent anxiolytics having reduced side effects compared to known anxiolytics. Also pharmaceutical compositions, intermediates and methods of treatment and synthesis are described.

  公式(I)的化合物：##STR1##其中R.sup.1、R.sup.3、R.sup.4、R.sup.7和R.sup.8如本文所述，D是氧或NR.sup.6，n为1或2，以及其生理上可接受的盐，有助于减少动物（如人类）的焦虑。这些化合物是具有减少副作用的强效抗焦虑剂，与已知的抗焦虑剂相比。还描述了药物组合物、中间体和治疗和合成方法。
• Substituted pyrazolopyrimidines
  申请人：Bacon R. Edward

  公开号：US20070281949A1

  公开（公告）日：2007-12-06

  The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).

  本发明涉及化学组合物、其制备方法以及组合物的用途。特别是，本发明涉及包括式（I）的取代杂环嘧啶的组合物：其中R1、R2、R3、R4、R5、X、W和环A如本文所定义；取代杂环嘧啶的药物组合物；以及它们在治疗慢性神经退行性疾病、神经创伤性疾病、抑郁症和/或糖尿病中的用途。更具体地，本发明涉及式（I）的取代吡唑嘧啶。
• Pyrazolopyridine cycloalkanones and process for their preparation
  申请人：ICI Americas Inc.

  公开号：US04546104A1

  公开（公告）日：1985-10-08

  Novel tetrahydropyrazolo-[3,4-b]quinolinones, cyclopenta[b]pyrazolo-[4,3-e]pyridinones and cyclohepta[b]-pyrazolo[4,3-e]pyridinones, useful as anxiolytics having reduced side effects, are disclosed, including methods of preparation, pharmaceutical compositions containing them and intermediates used in their preparation.

  新型四氢吡唑并[3,4-b]喹啉酮、环戊[b]吡唑并[4,3-e]吡啶酮和环庚[b]-吡唑并[4,3-e]吡啶酮，作为具有减少副作用的抗焦虑药物被披露，包括其制备方法、含有它们的药物组合物和用于其制备的中间体。
• Pyrazolopyridine compounds, and intermediates, useful as anxiolytic
  申请人：ICI Americas Inc.

  公开号：US04645838A1

  公开（公告）日：1987-02-24

  Compounds of the formula (I): ##STR1## wherein R.sup.1, R.sup.3, R.sup.4, R.sup.7 and R.sup.8 are as described herein, D is oxygen, n is 1 or 2 and the physiologically acceptable salts thereof useful in reducing anxiety in an animal such as man. The compounds are potent anxiolytics having reduced side effects compared to known anxiolytics. Also pharmaceutical compositions, intermediates and methods of treatment and synthesis are described.

  式(I)的化合物：##STR1##其中R.sup.1，R.sup.3，R.sup.4，R.sup.7和R.sup.8如本文所述，D为氧，n为1或2，以及其生理上可接受的盐，在动物（如人）中有减轻焦虑的作用。这些化合物是具有较低副作用的有效抗焦虑剂，与已知的抗焦虑剂相比具有减少的副作用。此外，还描述了制药组合物、中间体、治疗和合成方法。